Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
LIVONIA, Mich., June 01, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.
| LD Micro Invitational | |||
| Date: | Tuesday, June 6th | ||
| Time: | 4:00 pm Pacific Time | ||
| Presenter: | Charles Bisgaier, Ph.D., Chief Scientific Officer | ||
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | ||
| Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8th | ||
| Time: | 4:00pm Eastern Time | ||
| Presenter: | Lee Golden, MD, Chief Medical Officer | ||
| Location: | Grand Hyatt Hotel, Imperial Ballroom | ||
| Webcast: | http://wsw.com/webcast/jeff105/gemp | ||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734)-245-1700
